Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany

BACKGROUND: Sacituzumab govitecan has been recently approved by the USFDA and EMA for the treatment of patients with metastatic triple-negative breast cancer (mTNBC). We report real-world safety and effectiveness in patients with mTNBC receiving sacituzumab govitecan treatment at a breast cancer cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinisch, Mattea, Bruzas, Simona, Spoenlein, Jennifer, Shenoy, Satyendra, Traut, Alexander, Harrach, Hakima, Chiari, Ouafaa, Cremer, Efsthatia, Ataseven, Beyhan, Gubelt, Lars, Kuemmel, Sherko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542232/
https://www.ncbi.nlm.nih.gov/pubmed/37789989
http://dx.doi.org/10.1177/17588359231200454

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542232/
https://www.ncbi.nlm.nih.gov/pubmed/37789989
http://dx.doi.org/10.1177/17588359231200454

Ejemplares similares